{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:30:53Z","timestamp":1761895853006},"reference-count":28,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2014,4,2]],"date-time":"2014-04-02T00:00:00Z","timestamp":1396396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2014,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Mycosis fungoides (<jats:styled-content style=\"fixed-case\">MF<\/jats:styled-content>) is the most common form of primary cutaneous T\u00a0cell lymphoma. Psoralen combined with ultraviolet A (<jats:styled-content style=\"fixed-case\">PUVA<\/jats:styled-content>) is a first\u2010line treatment for early\u2010stage disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>This study was conducted to assess the clinical effectiveness of and tolerance to <jats:styled-content style=\"fixed-case\">PUVA<\/jats:styled-content> monotherapy in <jats:styled-content style=\"fixed-case\">MF<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We retrospectively reviewed the files of patients who received <jats:styled-content style=\"fixed-case\">PUVA<\/jats:styled-content> for stage I disease. The study included 31 patients, of whom 32% presented with stage Ia and 67% with stage Ib disease, and 68% presented with patch and 32% with plaque disease. All patients received treatment three times per week.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Complete response (<jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>) was achieved in 71% of patients. The median cumulative dose of <jats:styled-content style=\"fixed-case\">UVA<\/jats:styled-content> at <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content> was 211.7\u00a0J\/cm<jats:sup>2<\/jats:sup>. There was a significant difference in median cumulative dose at <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content> between patients with plaque and patch disease, respectively, but not between patients with stage Ia and Ib disease. Median disease\u2010free survival (<jats:styled-content style=\"fixed-case\">DFS<\/jats:styled-content>) was 230\u00a0weeks. Patients with patch disease achieved longer <jats:styled-content style=\"fixed-case\">DFS<\/jats:styled-content> than those with plaque disease (<jats:italic>P\u00a0<\/jats:italic>=\u00a00.004), although <jats:styled-content style=\"fixed-case\">DFS<\/jats:styled-content> was similar in stage Ia and Ib patients. Of the patients who received maintenance therapy, 58% relapsed. Univariate analysis showed patch disease to be a predictive factor for <jats:styled-content style=\"fixed-case\">CR<\/jats:styled-content>, but no predictors of relapse were identified. A total of 71% of patients developed clinical adverse reactions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Psoralen with <jats:styled-content style=\"fixed-case\">UVA<\/jats:styled-content> is a safe and effective treatment for early\u2010stage <jats:styled-content style=\"fixed-case\">MF<\/jats:styled-content>. Patch disease responds more favorably than plaque disease and is associated with a longer period of <jats:styled-content style=\"fixed-case\">DFS<\/jats:styled-content>. Maintenance treatment does not appear to reduce recurrence. Current evidence suggests that the proposed revision to the classification of <jats:styled-content style=\"fixed-case\">MF<\/jats:styled-content>, which takes into account the extent and type of disease, more accurately predicts response to <jats:styled-content style=\"fixed-case\">PUVA<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ijd.12425","type":"journal-article","created":{"date-parts":[[2014,4,3]],"date-time":"2014-04-03T02:18:01Z","timestamp":1396491481000},"page":"1417-1422","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Treatment of stage <scp>I<\/scp>a and <scp>I<\/scp>b mycosis fungoides with psoralen <scp>UVA<\/scp> monotherapy: an observational study in tertiary hospitals in the <scp>C<\/scp>anary <scp>I<\/scp>slands"],"prefix":"10.1111","volume":"53","author":[{"given":"Zaida","family":"Hern\u00e1ndez","sequence":"first","affiliation":[{"name":"Department of Dermatology Complejo Hospitalario Universitario Insular Materno\u2010Infantil Maternity and Children's Hospital University Hospital Complex Las Palmas de Gran Canaria Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeray","family":"Pe\u00f1ate","sequence":"additional","affiliation":[{"name":"Department of Dermatology Complejo Hospitalario Universitario Insular Materno\u2010Infantil Maternity and Children's Hospital University Hospital Complex Las Palmas de Gran Canaria Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Buenaventura","family":"Hern\u00e1ndez\u2010Mach\u00edn","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital Virgen de las Nieves El Hierro Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"P\u00e9rez\u2010M\u00e9ndez","sequence":"additional","affiliation":[{"name":"Dermatology Research Unit University of La Laguna San Crist\u00f3bal de la Laguna Tenerife Spain"},{"name":"Department of Dermatology University Hospital Nuestra Se\u00f1ora de Candelaria Santa Cruz de Tenerife Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Su\u00e1rez\u2010Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospital Nuestra Se\u00f1ora de Candelaria Santa Cruz de Tenerife Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Department of Dermatology Complejo Hospitalario Universitario Insular Materno\u2010Infantil Maternity and Children's Hospital University Hospital Complex Las Palmas de Gran Canaria Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Fern\u00e1ndez\u2010de\u2010Misa","sequence":"additional","affiliation":[{"name":"Dermatology Research Unit University of La Laguna San Crist\u00f3bal de la Laguna Tenerife Spain"},{"name":"Department of Dermatology University Hospital Nuestra Se\u00f1ora de Candelaria Santa Cruz de Tenerife Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,4,2]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3502"},{"key":"e_1_2_6_3_1","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1001\/archderm.136.4.504","article-title":"Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients","volume":"136","author":"van Doorn R","year":"2000","journal-title":"Arch Dermatol"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-055749"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.7665"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2008.0033"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.01.025"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0781.2011.00559.x"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197608)38:2<683::AID-CNCR2820380210>3.0.CO;2-V"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.0630"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11156.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(18)30059-5"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(84)70030-2"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.141.3.305"},{"key":"e_1_2_6_15_1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2340\/00015555614751","article-title":"Photochemotherapy (PUVA) in the pre\u2010tumor stage of mycosis fungoides: a report from the Scandinavian Mycosis Fungoides Study Group","volume":"61","author":"Molin L","year":"1981","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_6_16_1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2340\/0001555576475478","article-title":"PUVA in early mycosis fungoides may give longterm remission and delay extracutaneous spread","volume":"76","author":"Roupe G","year":"1996","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(95)90241-4"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-3083.2003.00614_10.x"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.3.325"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1396-0296.2003.01639.x"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1396-0296.2003.01641.x"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1396-0296.2003.01640.x"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1396-0296.2003.01647.x"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03500.x"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2010.04833.x"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1396-0296.2003.01642.x"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2008.03680.x"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0b013e3283436e5d"},{"key":"e_1_2_6_29_1","first-page":"561","article-title":"Proceedings of the workshop on cutaneous T\u00a0Cell lymphomas (Mycosis Fungoides and S\u00e9zary Syndrome) introduction","volume":"63","author":"Lamberg SI","year":"1979","journal-title":"Cancer Treat Rep"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijd.12425","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.12425","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T15:52:14Z","timestamp":1695484334000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.12425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,2]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["10.1111\/ijd.12425"],"URL":"https:\/\/doi.org\/10.1111\/ijd.12425","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,2]]},"assertion":[{"value":"2014-04-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}